Archive

Author: Anand Swaminathan

REBEL Cast Ep97: The NoPAC Trial – TXA for Epistaxis?

Background: Epistaxis is a common Emergency Department (ED) complaint with over 450,000 visits per year and a lifetime incidence of 60% (Gifford 2008, Pallin 2005). Standard anterior epistaxis treatment consists of holding pressure, use of local vasoconstrictors, topical application of …

Read More
Head, Eye, Ear, Nose, and Throat

REBEL Core Cast 50.0 – Superficial Venous Thrombosis

Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation.  The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.

Read More
Hematology and Oncology

Does D Stand for Decrease Deterioration + Death? – The Jury is Out for Vitamin D in COVID

Update: This article was removed from the Lancet server on February 19th, 2021 (Link) Background: Vitamin D deficiency is common amongst critically ill patients and there has been ample speculation about a possible role for supplementation (with calcifediol) in the …

Read More
Infectious Disease

REBEL Cast Ep95: Colchicine in COVID (COLCORONA)? Don’t Believe the Hype.

Background: Science by press release. Not the way any of us would choose to operate but, the COVID pandemic has made this a reality. It’s vital that we understand that while pharmaceutical companies have a responsibility to release this information, …

Read More
Infectious Disease

REBEL Core Cast 49.0 – Abdominal Aortic Aneurysm (AAA)

Take Home Points Consider ruptured AAA in patients (especially those > 50 years of age) with unexplained hypotension, back or abdominal pain All ruptured AAAs should be considered unstable regardless of vital signs as rapid deterioration is common A ruptured …

Read More
Cardiovascular

Sponsored